Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus

Sunwen Chou, Ronald J. Ercolani, Katayoun Derakhchan

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The human cytomegalovirus (CMV) UL97 kinase inhibitor maribavir is in Phase III clinical trials as antiviral therapy, including use for infections refractory or resistant to standard therapy. To assess its activity in combination with approved and experimental CMV antivirals, and with the mTor inhibitor rapamycin (sirolimus), drug effects were tested by in vitro checkerboard assays and the data were analyzed using a three dimensional model based on an independent effects definition of additive interactions. Baseline virus and representative drug-resistant mutants were tested. According to the volume of synergy at 95% confidence, maribavir showed additive interactions with foscarnet, cidofovir, letermovir and GW275175X when tested against wild type and mutant viruses, strong antagonism with ganciclovir, and strong synergy with rapamycin, the latter suggesting a potentially useful therapeutic combination.

Original languageEnglish (US)
Pages (from-to)128-133
Number of pages6
JournalAntiviral Research
Volume157
DOIs
StatePublished - Sep 1 2018

Fingerprint

Sirolimus
Cytomegalovirus
Antiviral Agents
Pharmaceutical Preparations
Foscarnet
Viruses
Phase III Clinical Trials
Ganciclovir
Phosphotransferases
Therapeutics
Infection
maribavir

Keywords

  • Antagonism
  • Cytomegalovirus
  • Ganciclovir
  • Maribavir
  • Sirolimus
  • Synergism

ASJC Scopus subject areas

  • Pharmacology
  • Virology

Cite this

Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus. / Chou, Sunwen; Ercolani, Ronald J.; Derakhchan, Katayoun.

In: Antiviral Research, Vol. 157, 01.09.2018, p. 128-133.

Research output: Contribution to journalArticle

@article{1ef24bc903f041bf86322449bb2327d6,
title = "Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus",
abstract = "The human cytomegalovirus (CMV) UL97 kinase inhibitor maribavir is in Phase III clinical trials as antiviral therapy, including use for infections refractory or resistant to standard therapy. To assess its activity in combination with approved and experimental CMV antivirals, and with the mTor inhibitor rapamycin (sirolimus), drug effects were tested by in vitro checkerboard assays and the data were analyzed using a three dimensional model based on an independent effects definition of additive interactions. Baseline virus and representative drug-resistant mutants were tested. According to the volume of synergy at 95{\%} confidence, maribavir showed additive interactions with foscarnet, cidofovir, letermovir and GW275175X when tested against wild type and mutant viruses, strong antagonism with ganciclovir, and strong synergy with rapamycin, the latter suggesting a potentially useful therapeutic combination.",
keywords = "Antagonism, Cytomegalovirus, Ganciclovir, Maribavir, Sirolimus, Synergism",
author = "Sunwen Chou and Ercolani, {Ronald J.} and Katayoun Derakhchan",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.antiviral.2018.07.013",
language = "English (US)",
volume = "157",
pages = "128--133",
journal = "Antiviral Research",
issn = "0166-3542",
publisher = "Elsevier",

}

TY - JOUR

T1 - Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus

AU - Chou, Sunwen

AU - Ercolani, Ronald J.

AU - Derakhchan, Katayoun

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The human cytomegalovirus (CMV) UL97 kinase inhibitor maribavir is in Phase III clinical trials as antiviral therapy, including use for infections refractory or resistant to standard therapy. To assess its activity in combination with approved and experimental CMV antivirals, and with the mTor inhibitor rapamycin (sirolimus), drug effects were tested by in vitro checkerboard assays and the data were analyzed using a three dimensional model based on an independent effects definition of additive interactions. Baseline virus and representative drug-resistant mutants were tested. According to the volume of synergy at 95% confidence, maribavir showed additive interactions with foscarnet, cidofovir, letermovir and GW275175X when tested against wild type and mutant viruses, strong antagonism with ganciclovir, and strong synergy with rapamycin, the latter suggesting a potentially useful therapeutic combination.

AB - The human cytomegalovirus (CMV) UL97 kinase inhibitor maribavir is in Phase III clinical trials as antiviral therapy, including use for infections refractory or resistant to standard therapy. To assess its activity in combination with approved and experimental CMV antivirals, and with the mTor inhibitor rapamycin (sirolimus), drug effects were tested by in vitro checkerboard assays and the data were analyzed using a three dimensional model based on an independent effects definition of additive interactions. Baseline virus and representative drug-resistant mutants were tested. According to the volume of synergy at 95% confidence, maribavir showed additive interactions with foscarnet, cidofovir, letermovir and GW275175X when tested against wild type and mutant viruses, strong antagonism with ganciclovir, and strong synergy with rapamycin, the latter suggesting a potentially useful therapeutic combination.

KW - Antagonism

KW - Cytomegalovirus

KW - Ganciclovir

KW - Maribavir

KW - Sirolimus

KW - Synergism

UR - http://www.scopus.com/inward/record.url?scp=85050568684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050568684&partnerID=8YFLogxK

U2 - 10.1016/j.antiviral.2018.07.013

DO - 10.1016/j.antiviral.2018.07.013

M3 - Article

AN - SCOPUS:85050568684

VL - 157

SP - 128

EP - 133

JO - Antiviral Research

JF - Antiviral Research

SN - 0166-3542

ER -